FDA Determines Regulatory Review Period for JIVI Patent Extension Application

Summary

The U.S. Food and Drug Administration (FDA) has determined the regulatory review period for JIVI, a human biological product, following the submission of a patent extension application to the U.S. Patent and Trademark Office (USPTO). This determination is published as a notice, as required by law, and is related to the extension of JIVI's patent.